Condition

Relapsed Non-Hodgkin Lymphoma clinical trials and research

• 14Clinical trials
• 3NIH research projects
• 4Countries

Newest Relapsed Non-Hodgkin Lymphoma clinical trials

All recruiting trials (14)

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Combination treatment of pembrolizumab and ATRA for relapsed Hodgkin and Non-Hodgkin lymphoma

  This study is testing if a combination of two treatments, pembrolizumab and ATRA, can help adults with relapsed Hodgkin and Non-Hodgkin lymphoma feel better and improve their health.

  Recruiting at 2 sites Phase 2 Indiana University · Indianapolis, Indiana and 1 other locations · NCT06484920

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• Combining Chidamide and Linperlisib for treating difficult cases of follicular lymphoma

  This study is testing if combining two drugs, Chidamide and Linperlisib, can help people with tough cases of follicular lymphoma who haven't responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06158386

• IDP-023 treatment for advanced blood cancers

  This study is testing a new treatment called IDP-023, which uses special immune cells alone and with other medications to see if it can help people with advanced blood cancers like multiple myeloma and non-Hodgkin lymphoma.

  Recruiting at 9 sites Phase 1/2 Indapta Therapeutics, INC. · Los Angeles, California and 11 other locations · NCT06119685

• Ablative radiation before CAR-T therapy for high-risk lymphoma

  This study is testing if giving radiation therapy before CAR T-cell treatment can help people with high-risk lymphoma have better results.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06104592

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Testing SIRPant-M for patients with relapsed or refractory Non-Hodgkin's lymphoma

  This study is testing a new cell therapy called SIRPant-M to see if it can help people with relapsed or hard-to-treat Non-Hodgkin's lymphoma feel better.

  Recruiting at 3 sites Phase 1 SIRPant Immunotherapeutics, Inc. · Duarte, California and 2 other locations · NCT05967416

• Treatment of aggressive large B-cell lymphoma with LYL314

  This study is testing a new CAR T-cell therapy called LYL314 to see if it can effectively treat aggressive large B-cell lymphoma in different groups of patients.

  Recruiting at 35 sites Phase 1/2 Lyell Immunopharma, Inc. · Irvine, California and 34 other locations · NCT05826535

• Combination treatment for aggressive Non-Hodgkin's Lymphoma

  This study is testing a new combination of treatments for people with aggressive Non-Hodgkin's Lymphoma to see if it can help shrink their tumors when other treatments haven't worked.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT05260957

• CAR T-cell therapy targeting CD19 for aggressive lymphoma and leukemia

  This study is testing a new type of treatment using modified immune cells to see if it can help people with aggressive lymphoma or leukemia that hasn't responded to other treatments.

  Recruiting at 2 sites Phase 1/2 University of Alberta · Calgary, Alberta and 5 other locations · NCT03938987

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Multi-antigen T cell therapy for relapsed NHL

  A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11374461

• MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma

  This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11164733

• New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma

  This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-10922163

Related topics

Quick answers

How many Relapsed Non-Hodgkin Lymphoma clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in United States (12 trials), Australia (2 trials), Canada (2 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1/2: 5, Phase 1: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →